[1]印海娟,郑杰,董涛,等.复方苦参注射液联合新辅助化疗对宫颈癌患者CA125、CA199、CEA的影响[J].西部中医药,2021,34(04):105-108.[doi:10.12174/j.issn.2096-9600.2021.04.26]
　YIN Haijuan,ZHENG Jie,DONG Tao,et al.Effects of Compound Kushen Injection Combined with Neoadjuvant Chemotherapy on CA125, CA199 and CEA in Patients with Cervical Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(04):105-108.[doi:10.12174/j.issn.2096-9600.2021.04.26]
点击复制

复方苦参注射液联合新辅助化疗对宫颈癌患者CA125、CA199、CEA的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年04期
页码:
105-108
栏目:
衷中参西
出版日期:
2021-04-15

文章信息/Info

Title:
Effects of Compound Kushen Injection Combined with Neoadjuvant Chemotherapy on CA125, CA199 and CEA in Patients with Cervical Cancer
作者:
印海娟1, 郑杰1, 董涛2, 姬钰滢1, 徐建余3
1.华北理工大学研究生院,河北 唐山 063000
2.秦皇岛市第一医院
3.华北理工大学生命科学学院
Author(s):
YIN Haijuan1, ZHENG Jie1, DONG Tao2, JI Yuying1, XU Jianyu3
1.Graduate School, North China University of Science and Technology, Tangshan 063000, China
2.Qinhuangdao City The First Hospital
3.College of Life Sciences, North China University of Science and Technology
关键词:
宫颈癌; 复方苦参注射液; 新辅助化疗; 血清肿瘤标志物; 免疫功能
Keywords:
cervical cancer; compound injection; neoadjuvant chemotherapy; serum tumor markers; immunological function
分类号:
R737.3
DOI:
10.12174/j.issn.2096-9600.2021.04.26
摘要:
目的探讨复方苦参注射液联合新辅助化疗治疗宫颈癌的疗效及对血清糖类抗原125（carbohydrate antigen 125，CA125）、糖类抗原199（cancer antigen 199，CA199）、癌胚抗原（carcinoembryonic antigen，CEA）的影响。 方法选择宫颈癌患者102例，按随机数字表法分为对照组（50例）和观察组（52例）。对照组采用新辅助化疗治疗，观察组在对照组治疗基础上加用复方苦参注射液治疗。连续治疗2个疗程后，比较两组临床疗效、血清肿瘤标志物、免疫功能、毒副反应。 结果总缓解率观察组为88.46%（46/52），高于对照组的72.00%（36/50），差异有统计学意义（P＜0.05）。治疗后，观察组CA125、CA199及CEA水平均低于对照组，差异有统计学意义（P＜0.05）。治疗后，观察组CD4+、CD3+、CD4+/CD8+水平高于对照组，CD8+水平低于对照组，差异有统计学意义（P＜0.05）。观察组肾功能损伤、胃肠道反应、白细胞减少及脱发等不良反应发生率低于对照组，差异有统计学意义（P＜0.05）；两组骨髓抑制发生率相比，差异无统计学意义（P＞0.05）。 结论采用复方苦参注射液联合新辅助化疗治疗宫颈癌可降低血清肿瘤标志物水平，提高机体免疫功能，减轻新辅助化疗的毒副反应。
Abstract:
ObjectiveTo explore clinical effects of compound Kushen injection and neoadjuvant chemotherapy in treating cervical cancer and its influence on the levels of CA125, CA199 and CEA. MethodsAll 102 patients were divided into the control group (50 cases) and the observation group (52 cases) using random number table method. The control group adopted neoadjuvant chemotherapy, and the observation group were treated by compound Kushen injection based on Western medicine. To compare clinical effects, serum tumor markers, immunological function, toxic and adverse reaction between both groups when they were treated for two courses consecutively. ResultsTotal remission rate of the observation group was 88.46% (46/52), higher than 72.00% (36/50), and the difference showed statistical meaning (P<0.05). After treating, the observation group was lower than the control group in the levels of CA125, CA199 and CEA, and the difference was statistically significant (P<0.05). After the treatment, the levels of CD4+. CD3+. CD4+/CD8+ of the observation group were higher than these of the control group, the levels of CD8+ lower than that of the control group, and the difference had statistical meaning (P<0.05).The observation group was lower than the control group in incidence of adverse reaction such as renal impairment, gastrointestinal reaction, leukocytopenia, alopecia, etc and the difference showed statistical meaning (P<0.05); the difference showed no statistical meaning in bone marrow suppression incidence between both groups (P>0.05). ConclusionFor patients with cervical cancer, compound Kushen injection combined with neoadjuvant chemotherapy could lower the levels of serum tumor markers, raise body immunological function and alleviate toxic and adverse reaction caused by neoadjuvant chemotherapy.

相似文献/References:

[1]邵金博.郭立中应用“温阳法”保守治疗宫颈癌验案分析*[J].西部中医药,2014,27(06):37.
　SHAO Jinbo.On Professor Guo Lizhong′s Experience of Applying Conservative Therapy of "Yang-warming Method" to Cervical Carcinoma[J].Western Journal of Traditional Chinese Medicine,2014,27(04):37.
[2]樊慧妮.心理护理对宫颈癌患者生活质量的影响[J].西部中医药,2014,27(10):138.
[3]郭强蕊.CT诊断在卵巢癌和宫颈癌放射治疗前后的临床运用价值[J].西部中医药,2015,28(01):125.
[4]曲波,王海琳△,吴红彦,等.参芪抑瘤方联合新辅助化疗治疗中晚期宫颈癌临床疗效分析[J].西部中医药,2017,30(08):1.
　QU Bo,WANG Hailin,WU Hongyan,et al.An Analysis of Clinical Effects of ShenQi Tumor-inhibiting Prescriptions Jointed with Neoadjuvant Chemotherapy in Treating Cervical Carcinoma at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2017,30(04):1.
[5]孙曦,王洪旗,龚一竹,等.复方苦参注射液联合α-干扰素治疗慢性乙型肝炎55例[J].西部中医药,2018,31(12):95.
　SUN Xi,WANG Hongqi,GONG Yizhu,et al.Compound KuShen Injection and Interferon α-1b in Treating 55 Cases of Chronic Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2018,31(04):95.
[6]关崇丽,郑婧,王惠玲△.丹参酮ⅡA对人宫颈癌细胞增殖与凋亡的影响[J].西部中医药,2020,33(01):37.[doi:10.12174/j.issn.1004-6852.2020.01.10]
　GUAN Chongli,ZHENG jing,WANG Huiling.Effect of Tanshinone Ⅱ A on the Proliferation and Apoptosis of Human Cervical Cancer Cells[J].Western Journal of Traditional Chinese Medicine,2020,33(04):37.[doi:10.12174/j.issn.1004-6852.2020.01.10]
[7]李娟,何春晓,刘冬梅.中药封包联合盐酸坦洛新对宫颈癌术后尿潴留的防治[J].西部中医药,2020,33(02):120.[doi:10.12174/j.issn.1004-6852.2020.02.34]
　LI Juan,HE Chunxiao,LIU Dongmei.TCM Package Joined with Tamsulosin Hydrochloride in the Prevention and Treatment for Urinary Retention after the Surgery of Cervical Carcinoma[J].Western Journal of Traditional Chinese Medicine,2020,33(04):120.[doi:10.12174/j.issn.1004-6852.2020.02.34]
[8]陈静,褚福浩,金珠措姆,等.藏药普尔那提取物对宫颈癌海拉细胞增殖作用的研究[J].西部中医药,2021,34(06):18.[doi:10.12174/j.issn.2096-9600.2021.06.05]
　CHEN Jing,CHU Fuhao,Jinzhu Cuomu,et al.Study on the Effects of Tibetan Medicine Puerna Extract on the Proliferation of Hela Cells in Cervical Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(04):18.[doi:10.12174/j.issn.2096-9600.2021.06.05]
[9]邓歌.放射疗法配合黄药子汤保留灌肠治疗晚期宫颈癌临床观察[J].西部中医药,2021,34(06):103.[doi:10.12174/j.issn.2096-9600.2021.06.25]
　DENG Ge.Clinical Observation of Radiotherapy Combined with Retention Enema with Huangyaozi Decoction in the Treatment of Advanced Cervical Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(04):103.[doi:10.12174/j.issn.2096-9600.2021.06.25]
[10]董姣姣,李楠,白俊,等.贺丰杰教授从气阴两虚论治宫颈癌术后患者临证经验拾萃[J].西部中医药,2021,34(04):57.[doi:10.12174/j.issn.2096-9600.2021.04.14]
　DONG Jiaojiao,LI Nan,BAI Jun,et al.Professor He Fengjie′s Clinical Experience in Discussing and Treating the Patients after the Operation of Cervical Cancer of Qi and Yin Deficiency Pattern[J].Western Journal of Traditional Chinese Medicine,2021,34(04):57.[doi:10.12174/j.issn.2096-9600.2021.04.14]

备注/Memo

备注/Memo:
印海娟（1983—），女，在读硕士研究生，主管检验师。研究方向：病原生物学。秦皇岛市科技计划项目（201805A022）。
更新日期/Last Update: 2021-04-15